Prevalence of Urinary Incontinence and Evaluation of Related Factors in Patients With COPD
Prevalence of Urinary Incontinence and Evaluation of Related Factors in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: MELTEM UZUN, Ph.D(c)
- Phone Number: 05346390534
- Email: meuzun@sanko.edu.tr
Study Locations
-
-
Please Select
-
Gaziantep, Please Select, Turkey, 27060
- Recruiting
- Sanko University
-
Contact:
- MELTEM İ UZUN, Ph.D(c)
- Phone Number: 05346390534
- Email: meuzun@sanko.edu.tr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with COPD
Exclusion Criteria:
- 65 and above patients Patients with congenital anomalies that may cause incontinence Patients with neurological diagnosis that may cause incontinence
- Obese patients with BMI over 30
- Female patients with traumatic gynecological history
- Patients with incontinence after severe gynecological operation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MMRC Dyspnea score
Time Frame: First day
|
Grade shortness of breath that may occur during daily exercises.
"0" means shortness of breath with heavy exercise and 5 means shortness of breath even when dressing and undressing.
|
First day
|
|
COPD Assessment Test CAT
Time Frame: First day
|
It is an eight-item short, easy-to-apply test that measures the effects of COPD and deterioration in health status.
The change in two units or more at the individual patient level is clinically significant.
|
First day
|
|
ICIQ-SF (International Urinary Incontinence Consultation) Survey
Time Frame: First day
|
It consists of 6 questions.
In the first two questions, the date of birth and gender are questioned, while in the third question the incidence of urinary incontinence is questioned in the fourth question.
5. Question "How much incontinence affects your daily life?"
Is answered between 0 (does not affect it in any way) and 10 (very much affects) and makes you think that the quality of life gets worse as you get closer to 10.
In question 6, the time of incontinence is questioned.
The maximum value is 21.
The higher the score, the lower the quality of life.
|
First day
|
|
Urinary Distress Inventory
Time Frame: First day
|
It consists of 6 questions and is graded as a four-point Likert.
The first two questions address irritative symptoms (urgency, frequency, and pain), while questions 3 and 4 aim at stress symptoms, and the last two questions address obstructive or voiding symptoms.
|
First day
|
|
Leicester Cough Survey
Time Frame: First day
|
It consists of 19 items, three of which are physical, psychological and social.
The items in the Leicester Cough Questionnaire were selected by clinical effect factor method.
This method selects the subjects that the patients define as problems and differentiates them according to the importance of the patients.
Topics are also divided into fields.
The questionnaire is completed on a seven-point Likert Scale (1 = Always, 2 = Most of the time, 3 = Often, 4 = Sometimes, 5 = Occasionally, 6 = Rarely, 7 = Never).
Higher scores indicate better health status.
Total score; It is the sum of the scores of the three subheadings (physical, psychological and social).
|
First day
|
|
Activity-Self Assessment
Time Frame: First day
|
It is an individual-centered assessment tool consisting of 21 questions related to the individual's kendisi self alı related to the activity activity (how well it performs the activity) and value (how valuable / important the relevant activity is for itself).
The first 11 questions are skills; 12.-16.
questions between habits and 17.-21.
items related to requests.
|
First day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Meltem Uzun, PhD(c), Sanko University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Respiratory Tract Diseases
- Urologic Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Disease Attributes
- Urination Disorders
- Elimination Disorders
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Urinary Incontinence
- Enuresis
Other Study ID Numbers
Other Study ID Numbers
- Sanko
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.